Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964256 | 0.86 | AOC3 (0.54) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1586340 | 0.85 | SLC1A3 (0.54) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL4561509 | 0.83 | EPHX1 (0.49) | KMT2ACYP1A2CYP2D6EPHX1SMN1; SMN2 | |
| SCHEMBL1831820 | 0.83 | ALOX5 (0.44) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL11008921 | 0.82 | KMT2A (0.47) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL8870449 | 0.82 | ALDH1A1 (0.52) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL29291234 | 0.81 | CTSD (0.51) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL9475960 | 0.81 | ALDH1A1 (0.56) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL9675264 | 0.81 | KMT2A (0.55) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL1827749 | 0.81 | TDP1 (0.44) | KMT2ASLC1A3SLC1A2SLC1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-4500456-A | AND AZETIDINONE-4-SULFINIC ACID, OR SALT THEREOF | ELI LILLY AND COMPANY (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0019401-B1 | PROCESS FOR PREPARING ENAMINE DERIVATIVES, COMPOUNDS SO PRODUCED AND PROCESS FOR PREPARING A 3-HYDROXY-CEPHALOSPORIN | Lilly Industries Limited (GB) | 1984-03-21 | — | — | EP | disclosed |
| EP-0014567-B1 | PROCESSES FOR PREPARATION OF BETA-LACTAM COMPOUNDS | ELI LILLY AND COMPANY (US) | 1984-01-18 | — | — | EP | disclosed |
| US-4368156-A | USING POSITIVE HALOGEN REAGENT | ELI LILLY AND COMPANY (US) | 1983-01-11 | — | — | US | disclosed |
| EP-0060120-A1 | Process for preparing 4-haloazetidin-2-ones | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4223133-A | USING A TRIARYL PHOSPHITE-HALOGEN COMPLEX | ELI LILLY AND COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
| EP-0014567-A1 | Processes for preparation of beta-lactam compounds | ELI LILLY AND COMPANY (US) | 1980-08-20 | — | — | EP | disclosed |
| US-4211702-A | TRIARYLPHOSPHITE-HALOGEN COMPLEX HALOGENATING AGENT | ELI LILLY AND COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4176231-A | Process for preparing 3-exomethylenecepham sulfoxides | LILLY INDUSTRIES LIMITED (GB) | 1979-11-27 | — | — | US | disclosed |
| US-4159266-A | AZETIDINONE SULFINIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4052387-A | METHOD OF PREPARATION OF 3-METHYLENECEPHAMS | ELI LILLY AND COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
| US-4048163-A | Process for preparation of 7-alkoxy-3-chloromethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048160-A | Process for preparation of 7-alkoxy-3-bromomethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4042585-A | Process for preparation of 3-halomethylcephems | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4038275-A | PROCESS FOR PREPARATION OF 3-HYDROXYMETHYLCEPHEMS | ELI LILLY AND COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | KMT2A 4028/4885SLC1A3 1867/4885SLC1A2 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.